Keywords: tysabri, sales, improve, elan, 2nd-qtr, loss, irish
Tysabri sales improve Elan's 2nd-qtr loss 49%
Article | 04 August 2008
Irish biotechnology firm Elan's second-quarter 2008 net loss narrowed 49% year-on-year to $71.5 million, boosted by higher sales of Tysabri (natalizumab). Co-developed with ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Negative US patent ruling for Novo Nordisk on Prandin
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Daiichi Sankyo files for Japanese approval of Prasugrel
